Teva settles US states' drug price-fixing case

By Reuters News

- Teva Pharmaceutical Industries TEVA.TA has settled long-running litigation by most US states accusing the drugmaker and dozens of other defendants of conspiring to fix prices on dozens of generic drugs.

  • Chief Judge Michael Shea of the federal court in Hartford, Connecticut, put the case on hold on Monday after both sides reached an agreement in principle to settle, court records show. Settlement terms were not disclosed. The case was brought by 45 US states, Washington, DC and two US territories.

  • Teva did not immediately respond to requests for comment. The office of Connecticut Attorney General William Tong, whose state leads the litigation, did not immediately respond to similar requests.

  • The states accused Teva and other defendants of having in 2012 "embarked on one of the most egregious and damaging price-fixing conspiracies in the history of the United States," in which they allegedly agreed to maintain their "fair share" of each generic drug market while significantly raising prices on as many drugs as possible.

  • Prices skyrocketed in 2013 and 2014, the states said. Teva significantly raised prices on approximately 112 different generic drugs, and colluded with "high quality" competitors to raise prices on at least 86 of them, sometimes by more than 1,000%, the states added.

  • Shea oversees two other antitrust lawsuits by state attorneys general related to generic drugs.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.